a validated technology platform

Our virosome vaccine technology and know-how has been and continues to be validated through high value partnerships and collaboration with some of the world’s leading research funding organizations, pharma and biotech companies.


We have been able to attract continued grant funding for our promising HIV and malaria vaccines, while we have signed several license, collaboration and R&D project agreements with large Pharma and with biotech companies in the immune oncology and allergy space.



Early 2014, our RSV virosome vaccine and technology was selected by Astellas – ClearPath as the most promising RSV vaccine for the Astellas vaccine franchise targeting infectious diseases. Following a thorough due diligence of Mymetics’ virosome IP, know-how and the RSV virosome vaccine preclinical results and construct, we signed an exclusive license and collaboration agreement for our RSV virosome based vaccine funded by Astellas, a leading Japanese pharma company.

On January 29, 2016 Mymetics announced that the collaboration agreement will be discontinued, with effective date July 25, 2016.

Mymetics is currently evaluating new possible partnerships around the RSV virosome vaccine IP, know-how and deep expertise that has been built during this collaboration. 


In close cooperation with the Texas Biomedical Research Institute, our HIV vaccine candidate obtained funding from the Bill & Melinda Gates Foundation to perform a study in non-human primates, replicating a smaller study in which the vaccine provided an unprecedented 100% protection in macaque monkeys. The Mymetics’ HIV vaccine is the first with a demonstrated ability to prevent viral transmission in primates.

On April 29, 2019, the National Institutes of Health ("NIH") awarded the Company and Texas Biomedical Research Institute ("Texas Biomed") later replaced with University of Louisiana at Lafayette, a five-year grant for the project. The project started on May 1, 2019 and is planned for five years. The overall budget related to the project is USD 8,850k. See for more information below under Grant Financing.


Our virosome technology has been selected by PATH-MVI, the world leading malaria vaccine research funding organization, to be evaluated for a transmission blocking malaria vaccine based on the antigens of LMIV (NIAID-HIV).

Since 2017, Mymetics has been improving the malaria vaccine candidate against blood and liver stage of the Pf parasite. This is a collaboration with the Swiss Tropical Institute, Oxford University and the European Union Transvac2 program.


Since April 2020, Mymetics is collaborating with leading academic institutions like Baylor College of Medicine in Texas, the Amsterdam Medical Center (AMC) in the Netherlands, and Bern University Hospital in Switzerland and has received funding and services from Swiss Innovation Agency (Innosuisse) and the European Union under the Horizon 2020 Transvac2 program.

Social media

Follow Us

Grant Financing

Thermostable virosome-based vaccines
From May 2015 to November 2018, Mymetics led a project with a consortium of companies which have been awarded a total of €8.4 million in grant financing. 
The project had as objective to develop GMP cold-chain independent and thermostable virosome vaccines. The project has received €5.3 million funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 646122, and €3.1 million from the Swiss Secretariat for Education, Research and Innovation.
The project has been very successful and has allowed Mymetics to develop GMP pilot lines to produce a thermostable powder forms for its HIV vaccine candidate, which now can resist long term cold chain interruptions and be provided by intra-nasal, sub lingual or oral tablet.  
Thermostable Mucosal HIV vaccine
On April 29, 2019, the National Institutes of Health (“NIH”) awarded the Company and Texas Biomedical Research Institute (“Texas Biomed”) a five-year grant for the project called “Cold Chain-independent, Needle-free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels”. The project started on May 1, 2019 and is planned for five years. The overall budget related to the project is USD 8,850k
It was initially co-led by Texas Biomed, but due to the move of Dr. Ruth Ruprecht, the Co-Principal Investigator, to the University of Louisiana at Lafayette (“ULL”) at the end of 2019, ULL has become the co-lead with Mymetics for this project.
The project has the objective to prepare the Company’s promising HIV-1 vaccine candidate for clinical trials, by first executing non-human primate (“NHP”) studies, where the test subjects will be receiving Mymetics’ virosome based HIV-1 vaccine candidate by several intra-muscular and intra-nasal applications, followed by rectal challenges. This awarded grant from the NIH can continue some of the developments that were achieved during the European Horizon 2020 project.

About us
Mymetics history

More than 30 years of experience in the field of virosome vaccines, a unique R&D expertise, and intellectual property rights, makes Mymetics the global leader in this field. A focused strategy based on a sound scientific approach have resulted in the development of a rich pipeline of vaccine candidates...

Read more


Few companies in the world have developed such a powerful technology platform and a unique know-how to develop next-generation vaccines for infectious diseases and immunotherapies for allergies and oncology...

Read more